Abstract
The light sources used in current photodynamic therapy are mainly lasers or light emitting diodes, which are not suitable to treat large-volume tumors and those located in the inner body. To overcome the limitation, we propose an in situ light source to activate the photosensitizer and kill the cancer cells directly. In the present work, we use luminol as light source and meso-tetraphenylporphyrin as the photosensitizer. According to the results, cells incubated with meso-tetraphenylporphyrin, subsequently triggered by luminol, decreased significantly in assays including cell viability and cytotoxicity, while the other groups showed only minor differences. The flow cytometric and fluorescent microscopy analysis showed similar results as well. In the analysis of cell death pathway, cell shrinkage was noticed after photodynamic therapy treatment, which might refer to apoptosis. Briefly, we suggest that luminol is a promising light source in meso-tetraphenylporphyrin-mediated photodynamic therapy for its greater penetration depth and well matched emission wavelength.
Keywords: In situ, light source, luminal, meso-tetraphenylporphyrin, photodynamic therapy, light sources, current photodynamic, large-volume tumors, photosensitizer, apoptosis
Current Medicinal Chemistry
Title:Luminol As In Situ Light Source in Meso-Tetraphenylporphyrin-Mediated Photodynamic Therapy
Volume: 20 Issue: 9
Author(s): L. Huang, Ti-Chen Chen and Feng-Huei Lin
Affiliation:
Keywords: In situ, light source, luminal, meso-tetraphenylporphyrin, photodynamic therapy, light sources, current photodynamic, large-volume tumors, photosensitizer, apoptosis
Abstract: The light sources used in current photodynamic therapy are mainly lasers or light emitting diodes, which are not suitable to treat large-volume tumors and those located in the inner body. To overcome the limitation, we propose an in situ light source to activate the photosensitizer and kill the cancer cells directly. In the present work, we use luminol as light source and meso-tetraphenylporphyrin as the photosensitizer. According to the results, cells incubated with meso-tetraphenylporphyrin, subsequently triggered by luminol, decreased significantly in assays including cell viability and cytotoxicity, while the other groups showed only minor differences. The flow cytometric and fluorescent microscopy analysis showed similar results as well. In the analysis of cell death pathway, cell shrinkage was noticed after photodynamic therapy treatment, which might refer to apoptosis. Briefly, we suggest that luminol is a promising light source in meso-tetraphenylporphyrin-mediated photodynamic therapy for its greater penetration depth and well matched emission wavelength.
Export Options
About this article
Cite this article as:
Huang L., Chen Ti-Chen and Lin Feng-Huei, Luminol As In Situ Light Source in Meso-Tetraphenylporphyrin-Mediated Photodynamic Therapy, Current Medicinal Chemistry 2013; 20 (9) . https://dx.doi.org/10.2174/0929867311320090008
DOI https://dx.doi.org/10.2174/0929867311320090008 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics
Current Pharmaceutical Design Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Current Molecular Medicine Chemokine Receptor-directed Agents as Novel Anti-HIV-1 Therapies
Current Topics in Medicinal Chemistry Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Nanotechnology Allied to Nitric Oxide Release Materials for Dermatological Applications
Current Nanoscience HIV-1 Integrase Inhibition: Binding Sites, Structure Activity Relationships and Future Perspectives
Current Medicinal Chemistry Nanoparticles Improve Biological Functions of Phthalocyanine Photosensitizers Used for Photodynamic Therapy
Current Drug Metabolism Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Nanotechnology-based Colorimetric Approaches for Pathogenic Virus Sensing: A Review
Current Medicinal Chemistry Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology Low Density Lipoprotein Receptor-Related Proteins (LRPs), Alzheimers and Cognition
Current Drug Targets - CNS & Neurological Disorders